SlideShare a Scribd company logo
1 of 24
UCSF Lean LaunchPad For Life Sciences
October 8, 2013
Todd Morrill

Customer Segmentation
Diagnostics Cohort D-1
1
Customer interviews
Customer interviews

•
•
•
•

Draw them out
Don’t worry about money
Use google to find prospects
Don’t piss me off
Today
• Value Proposition

• BMC fit and fitness

• What is a Customer Segment

• Our cross to bear…
Value Propositions are NOT complex
•
•
•
•
•

More accurate results, faster!
Higher sensitivity with less sample volume
Accurate ranking of treatment options
Easy-to-use cosmic ray gun
Portable nuclear warhead

But the environment is…
•

VP maps onto CS

•

• No Value Proposition, no Customer Segment
• Too many value propositions, not a Customer Segment
VPs for each ‘customer’ in the ecosystem, to the extent possible
5
How we will fit DX into the BMC

CLINICAL
TRIALS

REGULATION

IP

REIMBURSEMENT

6
Who is a Customer?
•
•
•
•

Someone who has a NEED which can be satisfied by your VPs
Someone who has a WANT which can be satisfied
Someone who can be IDENTIFIED
Someone who can be DIFFERENTIATED
© 2012 Steve Blank
Customer Archetype:

Joe “Dude” Marrama
• Loves to ski, surf, rock climb
• Salary ~100K/year
• Looking for something to do
when the surf’s blown out
• Intimidated by cost and learning
curve of kiting

“Companies need to offer more entry level
packages."
Matt Sexton
Founder Collegiate Kiteboarding Association
Results:

Our Customers
• Professional Kite Surfers
• Solely concerned with performance
• Average Kite Surfer
• Performance and cost sensitive
• “One less thing to carry” effect
• Prospective Kite Surfer
• Cost sensitive
• Learning barrier
Meet Xing Xie
International Graduate Student at Stanford
• Engineering graduate student
Xing

Art

– Receives financial package to cover tuition,
fees, insurance and living expenses

• Chinese 4-2-1 family
– No siblings, spoiled by parents
– High disposable income

• 1st time to America
– No credit score, SSN, or US address
– Strong ties to his community in China

• Academically responsible
– Completes all homework on time

• Financially responsible
– Pays all bills on time and in full

• Social network is similarly responsible
Customer Segments?
•
•
•

•

•
•

x
Kids
Boys
Adults

Kids under 10 with disposable
income (and who are thirsty)
Boys who like to watch machines
working, like the juicer machine
Dads and Moms who are walking
past our stand in the afternoon

Consider ‘Un-customer segments’
12
Good segmentation?

Need vs Want
Definitions: Four Types of Markets
Existing
Market

Resegmented
Market

New
Market

• Existing Market
– Faster/Better = High end

• Resegmented Market
– Niche = marketing/branding driven
– Cheaper = low end

• New Market
– Cheaper/good enough can create a new class of
product/customer
– Innovative/never existed before

• Clone Market
• Local adaptation

Clone
Market
Because you are here..
Because you are special…
hypothesize now

CLINICAL
TRIALS

IP

REGULATION
REIMBURSEMENT

16
Know your regulator
• Food and Drug Administration (FDA)
– Center for Devices and Radiological Health

•
•
•
•
•

USDA
European agencies (EMEA, national level)
Japanese Ministry of Health and Welfare
Chinese (SFDA)
Health Canada
Regulation
•

Invitro diagnostic products (IVD) are those reagents, instruments, and systems
intended for use in diagnosis of disease or other conditions, including a
determination of the state of health, in order to cure, mitigate, treat, or prevent
disease or its sequelae. Such products are intended for use in the collection,
preparation, and examination of specimens taken from the human body. [21 CFR
809.3]

•

IVDs are medical devices as defined in section 210(h) of the Federal Food, Drug,
and Cosmetic Act, and may also be biological products subject to section 351 of
the Public Health Service Act. Like other medical devices, IVDs are subject to
premarket and postmarket controls. IVDs are also subject to the Clinical Laboratory
Improvement Amendments (CLIA '88) of 1988.

•

What isn’t an IVD?
–
–

In vivo
Treatments
Regulatory classes for diagnostics
•

Class I (low to moderate risk): general controls

•

Class II (moderate to high risk): general controls and Special Controls (510(k)) aka PMN
–
–
–
–
–

•

Performance standards
Postmarket surveillance
Patient registries
Special labeling requirements
Premarket data requirements

Class III (high risk): general controls and Premarket Approval (PMA)
–
–

Under federal law, class III devices are subject to approval of a Premarket Approval Application
(PMA).
Devices that are not within a type marketed before the date of the Medical Device Amendments of
1976 – referred to preamendments devices – are classified into class III automatically under federal
law.. In addition, the FDA classifies into class III devices intended to be used in supporting or
sustaining human life or preventing impairment of human health, or that may present a potential
unreasonable risk of illness or injury for which general controls and special controls are insufficient to
provide reasonable assurance of the safety and effectiveness of a device, or for which there is
insufficient information to make such a determination.

http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm#class_1
Believe it or not…
Regulators are part of your
customer set
1. Find out which regulator
and sub-agency is likely to
be yours
2. Find out the process for
regulation and validation
3. Map them into your
ecosystem
Who pays for healthcare?
What is Reimbursement?
•

Reimbursement for procedures and
services performed by providers is made
by commercial payers or federal
intermediaries acting on behalf of a halfdozen programs. Reimbursement is
based on claims and documentation
filed by providers using medical
diagnosis and procedure codes.

•

Commercial payers must use standards
defined by the U.S. Department of
Health and Human Services (HHS) but
are largely regulated state-by-state. Save
for specific national mandates such as
reimbursement for childbirth,
commercial payers determine their own
rules of medical necessity or payment
and reimbursement fee schedules.
Federal intermediaries are regulated as
contractors by the Centers for Medicare
& Medicaid Services (CMS).

•

The Current Procedural
Terminology (CPT) code set is a medical
code set maintained by the American
Medical Association. The CPT code set
(copyright protected by the AMA)
describes medical, surgical, and
diagnostic services and is designed to
communicate uniform information
about medical services and procedures
among physicians, coders, patients,
accreditation organizations, and payers
for administrative, financial, and
analytical purposes
Like it or not…
Reimbursers and code
allocators are part of your
customer set
1. Find out which code groups
you may fit into
2. Find out the value for them
3. Find out the process for
assignment and approval
4. Map them into your
ecosystem
Next week
• Standard slides as per the syllabus
• Plus
– Ecosystem overview
– Regulation overview
– Reimbursement overview

More Related Content

What's hot

Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligenceferiel abidi
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsJITHIN K JOY
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueRobert Sturm
 
ETHICAL ISSUES IN BIOMEDICAL RESEARCH
ETHICAL ISSUES IN BIOMEDICAL RESEARCHETHICAL ISSUES IN BIOMEDICAL RESEARCH
ETHICAL ISSUES IN BIOMEDICAL RESEARCHHealth Forager
 
Abriviated new drug application
Abriviated new drug applicationAbriviated new drug application
Abriviated new drug applicationGaurav Kr
 
Online SAE reporting by CDSCO//Effective from 14/Mar/2021
Online SAE reporting by CDSCO//Effective from 14/Mar/2021 Online SAE reporting by CDSCO//Effective from 14/Mar/2021
Online SAE reporting by CDSCO//Effective from 14/Mar/2021 Anupam Bendre
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...IHS
 
Rx to OTC switch by Dr. Zubair Ali
Rx to OTC switch by Dr. Zubair AliRx to OTC switch by Dr. Zubair Ali
Rx to OTC switch by Dr. Zubair AliDr. Zubair Ali
 
Connecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesConnecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesMedpace
 
UCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesUCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesStanford University
 
UCSF Life Sciences: Week 6 Devices Partnerships
UCSF Life Sciences: Week 6 Devices PartnershipsUCSF Life Sciences: Week 6 Devices Partnerships
UCSF Life Sciences: Week 6 Devices PartnershipsStanford University
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentationAtul Rajpara
 
EudraVigilance: What's Changed?
EudraVigilance: What's Changed?EudraVigilance: What's Changed?
EudraVigilance: What's Changed?Covance
 
Argus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSArgus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSKatalyst HLS
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
PharmacovigilanceVignesh K
 
FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on BiologicsRobert Puopolo
 

What's hot (20)

[000012]
[000012][000012]
[000012]
 
Pharmaceutical competitive intelligence
Pharmaceutical competitive intelligencePharmaceutical competitive intelligence
Pharmaceutical competitive intelligence
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpments
 
How to report a serious adverse event
How to report a serious adverse eventHow to report a serious adverse event
How to report a serious adverse event
 
Drug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and RevenueDrug Development Life Cycle - Costs and Revenue
Drug Development Life Cycle - Costs and Revenue
 
ETHICAL ISSUES IN BIOMEDICAL RESEARCH
ETHICAL ISSUES IN BIOMEDICAL RESEARCHETHICAL ISSUES IN BIOMEDICAL RESEARCH
ETHICAL ISSUES IN BIOMEDICAL RESEARCH
 
Abriviated new drug application
Abriviated new drug applicationAbriviated new drug application
Abriviated new drug application
 
Online SAE reporting by CDSCO//Effective from 14/Mar/2021
Online SAE reporting by CDSCO//Effective from 14/Mar/2021 Online SAE reporting by CDSCO//Effective from 14/Mar/2021
Online SAE reporting by CDSCO//Effective from 14/Mar/2021
 
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
Pharmaceutical Lifecycle Management Challenges - Slides from Pharmaceutical P...
 
Rx to OTC switch by Dr. Zubair Ali
Rx to OTC switch by Dr. Zubair AliRx to OTC switch by Dr. Zubair Ali
Rx to OTC switch by Dr. Zubair Ali
 
Connecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease StudiesConnecting the Dots for Rare Disease Studies
Connecting the Dots for Rare Disease Studies
 
UCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devicesUCSF Life Sciences Week 2 devices
UCSF Life Sciences Week 2 devices
 
UCSF Life Sciences: Week 6 Devices Partnerships
UCSF Life Sciences: Week 6 Devices PartnershipsUCSF Life Sciences: Week 6 Devices Partnerships
UCSF Life Sciences: Week 6 Devices Partnerships
 
Orphan drugs presentation
Orphan drugs presentationOrphan drugs presentation
Orphan drugs presentation
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
EudraVigilance: What's Changed?
EudraVigilance: What's Changed?EudraVigilance: What's Changed?
EudraVigilance: What's Changed?
 
Argus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLSArgus Screen Shots General Tab - Katalyst HLS
Argus Screen Shots General Tab - Katalyst HLS
 
Introduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical TrialsIntroduction to Phase 2 & 3 Clinical Trials
Introduction to Phase 2 & 3 Clinical Trials
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
FDA Presentation on Biologics
FDA Presentation on BiologicsFDA Presentation on Biologics
FDA Presentation on Biologics
 

Viewers also liked

UCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsUCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsStanford University
 
UCSF Life Sciences Week 1 Devices
UCSF Life Sciences Week 1 DevicesUCSF Life Sciences Week 1 Devices
UCSF Life Sciences Week 1 DevicesStanford University
 
UCSF Life Sciences Week 1 Therapeutics
UCSF Life Sciences Week 1 TherapeuticsUCSF Life Sciences Week 1 Therapeutics
UCSF Life Sciences Week 1 TherapeuticsStanford University
 
UCSF Life Sciences Week 2 digital health - Customer Sements
UCSF Life Sciences Week 2 digital health - Customer SementsUCSF Life Sciences Week 2 digital health - Customer Sements
UCSF Life Sciences Week 2 digital health - Customer SementsStanford University
 
UCSF Life Sciences Week 1 digital health - Value Proposition
UCSF Life Sciences Week 1 digital health - Value PropositionUCSF Life Sciences Week 1 digital health - Value Proposition
UCSF Life Sciences Week 1 digital health - Value PropositionStanford University
 
UCSF Life Sciences Week 2 Therapeutics: Customer Segments
UCSF Life Sciences Week 2 Therapeutics: Customer SegmentsUCSF Life Sciences Week 2 Therapeutics: Customer Segments
UCSF Life Sciences Week 2 Therapeutics: Customer SegmentsStanford University
 
New 7 tam, sam, tad, som explained
New 7 tam, sam, tad, som explainedNew 7 tam, sam, tad, som explained
New 7 tam, sam, tad, som explainedZiya-B
 
Value proposition for medical devices
Value proposition for medical devicesValue proposition for medical devices
Value proposition for medical devicesNealda Yusof
 
Magnamosis inc final presentation 12 10
Magnamosis inc final presentation 12 10Magnamosis inc final presentation 12 10
Magnamosis inc final presentation 12 10Stanford University
 
Mira Medicine Final Presentation
Mira Medicine Final PresentationMira Medicine Final Presentation
Mira Medicine Final PresentationStanford University
 
Final Project - InterNexus - NN Group
Final Project - InterNexus - NN GroupFinal Project - InterNexus - NN Group
Final Project - InterNexus - NN GroupAron James Miszlivetz
 
What it Takes to Innovate in Large Organizations
What it Takes to Innovate in Large OrganizationsWhat it Takes to Innovate in Large Organizations
What it Takes to Innovate in Large OrganizationsStanford University
 
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...J. Skyler Fernandes
 
Foursquare's 1st Pitch Deck
Foursquare's 1st Pitch DeckFoursquare's 1st Pitch Deck
Foursquare's 1st Pitch DeckRami Al-Karmi
 
Linkedin Series B Pitch Deck
Linkedin Series B Pitch DeckLinkedin Series B Pitch Deck
Linkedin Series B Pitch DeckJoseph Hsieh
 
The slide deck we used to raise half a million dollars
The slide deck we used to raise half a million dollarsThe slide deck we used to raise half a million dollars
The slide deck we used to raise half a million dollarsBuffer
 

Viewers also liked (18)

UCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnosticsUCSF Life Sciences Week 1 diagnostics
UCSF Life Sciences Week 1 diagnostics
 
UCSF Life Sciences Week 1 Devices
UCSF Life Sciences Week 1 DevicesUCSF Life Sciences Week 1 Devices
UCSF Life Sciences Week 1 Devices
 
UCSF Life Sciences Week 1 Therapeutics
UCSF Life Sciences Week 1 TherapeuticsUCSF Life Sciences Week 1 Therapeutics
UCSF Life Sciences Week 1 Therapeutics
 
UCSF Life Sciences Week 2 digital health - Customer Sements
UCSF Life Sciences Week 2 digital health - Customer SementsUCSF Life Sciences Week 2 digital health - Customer Sements
UCSF Life Sciences Week 2 digital health - Customer Sements
 
UCSF Life Sciences Week 1 digital health - Value Proposition
UCSF Life Sciences Week 1 digital health - Value PropositionUCSF Life Sciences Week 1 digital health - Value Proposition
UCSF Life Sciences Week 1 digital health - Value Proposition
 
UCSF Life Sciences Week 2 Therapeutics: Customer Segments
UCSF Life Sciences Week 2 Therapeutics: Customer SegmentsUCSF Life Sciences Week 2 Therapeutics: Customer Segments
UCSF Life Sciences Week 2 Therapeutics: Customer Segments
 
Knox final presentation
Knox final presentationKnox final presentation
Knox final presentation
 
New 7 tam, sam, tad, som explained
New 7 tam, sam, tad, som explainedNew 7 tam, sam, tad, som explained
New 7 tam, sam, tad, som explained
 
Value proposition for medical devices
Value proposition for medical devicesValue proposition for medical devices
Value proposition for medical devices
 
Magnamosis inc final presentation 12 10
Magnamosis inc final presentation 12 10Magnamosis inc final presentation 12 10
Magnamosis inc final presentation 12 10
 
Mira Medicine Final Presentation
Mira Medicine Final PresentationMira Medicine Final Presentation
Mira Medicine Final Presentation
 
Final Project - InterNexus - NN Group
Final Project - InterNexus - NN GroupFinal Project - InterNexus - NN Group
Final Project - InterNexus - NN Group
 
Team m patch aid v5 aug 31
Team m   patch aid v5 aug 31Team m   patch aid v5 aug 31
Team m patch aid v5 aug 31
 
What it Takes to Innovate in Large Organizations
What it Takes to Innovate in Large OrganizationsWhat it Takes to Innovate in Large Organizations
What it Takes to Innovate in Large Organizations
 
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...
The Best Startup Investor Pitch Deck & How to Present to Angels & Venture Cap...
 
Foursquare's 1st Pitch Deck
Foursquare's 1st Pitch DeckFoursquare's 1st Pitch Deck
Foursquare's 1st Pitch Deck
 
Linkedin Series B Pitch Deck
Linkedin Series B Pitch DeckLinkedin Series B Pitch Deck
Linkedin Series B Pitch Deck
 
The slide deck we used to raise half a million dollars
The slide deck we used to raise half a million dollarsThe slide deck we used to raise half a million dollars
The slide deck we used to raise half a million dollars
 

Similar to UCSF Life Sciences Week 2 Diagnostics

Regulatory 101 for Medical Device Start Ups
Regulatory 101 for Medical Device Start UpsRegulatory 101 for Medical Device Start Ups
Regulatory 101 for Medical Device Start UpsEMMAIntl
 
Financial Aspects of Genetic Testing - 1/11/22
Financial Aspects of Genetic Testing - 1/11/22Financial Aspects of Genetic Testing - 1/11/22
Financial Aspects of Genetic Testing - 1/11/22CHC Connecticut
 
mHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & SpaldingmHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & SpaldingLevi Shapiro
 
State Reform Survey Workgroup Meeting, February 2015
State Reform Survey Workgroup Meeting, February 2015State Reform Survey Workgroup Meeting, February 2015
State Reform Survey Workgroup Meeting, February 2015soder145
 
Requirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devicesRequirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devicesMike Sanchez
 
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe Jankowski
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe JankowskimHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe Jankowski
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe JankowskiLevi Shapiro
 
Presentation__Reimbursement Overview
Presentation__Reimbursement OverviewPresentation__Reimbursement Overview
Presentation__Reimbursement OverviewKendrik Lechner
 
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...Healthcare Network marcus evans
 
Marketplace 101
Marketplace 101Marketplace 101
Marketplace 101Lea Camara
 
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMedical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMichael Swit
 
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMedical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMichael Swit
 
US Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital HealthUS Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital HealthLevi Shapiro
 
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...Levi Shapiro
 
Health Care Domain & Testing Challenges
Health Care Domain & Testing ChallengesHealth Care Domain & Testing Challenges
Health Care Domain & Testing ChallengesMindfire Solutions
 
3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidosProColombia
 
3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidosProColombia
 
The future of mortgage regulation
The future of mortgage regulation   The future of mortgage regulation
The future of mortgage regulation Tony Moroney
 

Similar to UCSF Life Sciences Week 2 Diagnostics (20)

Regulatory 101 for Medical Device Start Ups
Regulatory 101 for Medical Device Start UpsRegulatory 101 for Medical Device Start Ups
Regulatory 101 for Medical Device Start Ups
 
Financial Aspects of Genetic Testing - 1/11/22
Financial Aspects of Genetic Testing - 1/11/22Financial Aspects of Genetic Testing - 1/11/22
Financial Aspects of Genetic Testing - 1/11/22
 
mHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & SpaldingmHealth Israel_US Reimbursement_David Farber_King & Spalding
mHealth Israel_US Reimbursement_David Farber_King & Spalding
 
State Reform Survey Workgroup Meeting, February 2015
State Reform Survey Workgroup Meeting, February 2015State Reform Survey Workgroup Meeting, February 2015
State Reform Survey Workgroup Meeting, February 2015
 
Requirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devicesRequirements for reimbursement of new medical devices
Requirements for reimbursement of new medical devices
 
ACA 101
ACA 101ACA 101
ACA 101
 
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe Jankowski
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe JankowskimHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe Jankowski
mHealth Israel_US Hospitals: Overcoming Barriers to Adoption_Joe Jankowski
 
Presentation__Reimbursement Overview
Presentation__Reimbursement OverviewPresentation__Reimbursement Overview
Presentation__Reimbursement Overview
 
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...
No Surprises Act and Price Transparency: Going Beyond Compliance to Build Pat...
 
Marketplace 101
Marketplace 101Marketplace 101
Marketplace 101
 
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMedical Device Advertising Law & Regulation
Medical Device Advertising Law & Regulation
 
Medical Device Advertising Law & Regulation
Medical Device Advertising Law & RegulationMedical Device Advertising Law & Regulation
Medical Device Advertising Law & Regulation
 
SUW US Gateway, Eeva Kiuru
SUW US Gateway, Eeva KiuruSUW US Gateway, Eeva Kiuru
SUW US Gateway, Eeva Kiuru
 
US Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital HealthUS Healthcare Reimbursement for MedTech & Digital Health
US Healthcare Reimbursement for MedTech & Digital Health
 
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
mHealth Israel_Synchronizing Reimbursement and Regulatory Activities_Amir Inb...
 
Health Care Domain & Testing Challenges
Health Care Domain & Testing ChallengesHealth Care Domain & Testing Challenges
Health Care Domain & Testing Challenges
 
3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos
 
3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos3. resultados del estudio de turismo de salud para estados unidos
3. resultados del estudio de turismo de salud para estados unidos
 
CDI
CDICDI
CDI
 
The future of mortgage regulation
The future of mortgage regulation   The future of mortgage regulation
The future of mortgage regulation
 

More from Stanford University

Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks  - 2022 Technology, Innovation & Great Power CompetitionTeam Networks  - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries  - 2022 Technology, Innovation & Great Power CompetitionTeam LiOn Batteries  - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum  - 2022 Technology, Innovation & Great Power CompetitionTeam Quantum  - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation  - 2022 Technology, Innovation & Great Power CompetitionTeam Disinformation  - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames  - 2022 Technology, Innovation & Great Power CompetitionTeam Wargames  - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power CompetitionStanford University
 
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion  - 2022 Technology, Innovation & Great Power Competition Team Acquistion  - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition Stanford University
 
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Stanford University
 
Altuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedAltuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedStanford University
 
Invisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedInvisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedStanford University
 
ānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learnedānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons LearnedStanford University
 
Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Stanford University
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Stanford University
 
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionTeam Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionTeam Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionTeam Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionTeam Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionTeam Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionStanford University
 
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Stanford University
 
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberLecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberStanford University
 

More from Stanford University (20)

Team Networks - 2022 Technology, Innovation & Great Power Competition
Team Networks  - 2022 Technology, Innovation & Great Power CompetitionTeam Networks  - 2022 Technology, Innovation & Great Power Competition
Team Networks - 2022 Technology, Innovation & Great Power Competition
 
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries  - 2022 Technology, Innovation & Great Power CompetitionTeam LiOn Batteries  - 2022 Technology, Innovation & Great Power Competition
Team LiOn Batteries - 2022 Technology, Innovation & Great Power Competition
 
Team Quantum - 2022 Technology, Innovation & Great Power Competition
Team Quantum  - 2022 Technology, Innovation & Great Power CompetitionTeam Quantum  - 2022 Technology, Innovation & Great Power Competition
Team Quantum - 2022 Technology, Innovation & Great Power Competition
 
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
Team Disinformation  - 2022 Technology, Innovation & Great Power CompetitionTeam Disinformation  - 2022 Technology, Innovation & Great Power Competition
Team Disinformation - 2022 Technology, Innovation & Great Power Competition
 
Team Wargames - 2022 Technology, Innovation & Great Power Competition
Team Wargames  - 2022 Technology, Innovation & Great Power CompetitionTeam Wargames  - 2022 Technology, Innovation & Great Power Competition
Team Wargames - 2022 Technology, Innovation & Great Power Competition
 
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
Team Acquistion  - 2022 Technology, Innovation & Great Power Competition Team Acquistion  - 2022 Technology, Innovation & Great Power Competition
Team Acquistion - 2022 Technology, Innovation & Great Power Competition
 
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition Team Climate Change - 2022 Technology, Innovation & Great Power Competition
Team Climate Change - 2022 Technology, Innovation & Great Power Competition
 
Altuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons LearnedAltuna Engr245 2022 Lessons Learned
Altuna Engr245 2022 Lessons Learned
 
Invisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons LearnedInvisa Engr245 2022 Lessons Learned
Invisa Engr245 2022 Lessons Learned
 
ānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learnedānanda Engr245 2022 Lessons Learned
ānanda Engr245 2022 Lessons Learned
 
Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef Gordian Knot Center Roundtable w/Depty SecDef
Gordian Knot Center Roundtable w/Depty SecDef
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
Team Army venture capital - 2021 Technology, Innovation & Great Power Competi...
 
Team Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power CompetitionTeam Catena - 2021 Technology, Innovation & Great Power Competition
Team Catena - 2021 Technology, Innovation & Great Power Competition
 
Team Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power CompetitionTeam Apollo - 2021 Technology, Innovation & Great Power Competition
Team Apollo - 2021 Technology, Innovation & Great Power Competition
 
Team Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power CompetitionTeam Drone - 2021 Technology, Innovation & Great Power Competition
Team Drone - 2021 Technology, Innovation & Great Power Competition
 
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power CompetitionTeam Short Circuit - 2021 Technology, Innovation & Great Power Competition
Team Short Circuit - 2021 Technology, Innovation & Great Power Competition
 
Team Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power CompetitionTeam Aurora - 2021 Technology, Innovation & Great Power Competition
Team Aurora - 2021 Technology, Innovation & Great Power Competition
 
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
Team Conflicted Capital Team - 2021 Technology, Innovation & Great Power Comp...
 
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - CyberLecture 8 - Technology, Innovation and Great Power Competition - Cyber
Lecture 8 - Technology, Innovation and Great Power Competition - Cyber
 

Recently uploaded

ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfJemuel Francisco
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomnelietumpap1
 
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxPoojaSen20
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinojohnmickonozaleda
 
Barangay Council for the Protection of Children (BCPC) Orientation.pptx
Barangay Council for the Protection of Children (BCPC) Orientation.pptxBarangay Council for the Protection of Children (BCPC) Orientation.pptx
Barangay Council for the Protection of Children (BCPC) Orientation.pptxCarlos105
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptxSherlyMaeNeri
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxiammrhaywood
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Mark Reed
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management SystemChristalin Nelson
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Seán Kennedy
 

Recently uploaded (20)

Raw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptxRaw materials used in Herbal Cosmetics.pptx
Raw materials used in Herbal Cosmetics.pptx
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdfGrade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
Grade 9 Quarter 4 Dll Grade 9 Quarter 4 DLL.pdf
 
ENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choomENGLISH6-Q4-W3.pptxqurter our high choom
ENGLISH6-Q4-W3.pptxqurter our high choom
 
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptxCulture Uniformity or Diversity IN SOCIOLOGY.pptx
Culture Uniformity or Diversity IN SOCIOLOGY.pptx
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
FILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipinoFILIPINO PSYCHology sikolohiyang pilipino
FILIPINO PSYCHology sikolohiyang pilipino
 
Barangay Council for the Protection of Children (BCPC) Orientation.pptx
Barangay Council for the Protection of Children (BCPC) Orientation.pptxBarangay Council for the Protection of Children (BCPC) Orientation.pptx
Barangay Council for the Protection of Children (BCPC) Orientation.pptx
 
Judging the Relevance and worth of ideas part 2.pptx
Judging the Relevance  and worth of ideas part 2.pptxJudging the Relevance  and worth of ideas part 2.pptx
Judging the Relevance and worth of ideas part 2.pptx
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptxECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
ECONOMIC CONTEXT - PAPER 1 Q3: NEWSPAPERS.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)Influencing policy (training slides from Fast Track Impact)
Influencing policy (training slides from Fast Track Impact)
 
Transaction Management in Database Management System
Transaction Management in Database Management SystemTransaction Management in Database Management System
Transaction Management in Database Management System
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...
 
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptxLEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
LEFT_ON_C'N_ PRELIMS_EL_DORADO_2024.pptx
 

UCSF Life Sciences Week 2 Diagnostics

  • 1. UCSF Lean LaunchPad For Life Sciences October 8, 2013 Todd Morrill Customer Segmentation Diagnostics Cohort D-1 1
  • 3. Customer interviews • • • • Draw them out Don’t worry about money Use google to find prospects Don’t piss me off
  • 4. Today • Value Proposition • BMC fit and fitness • What is a Customer Segment • Our cross to bear…
  • 5. Value Propositions are NOT complex • • • • • More accurate results, faster! Higher sensitivity with less sample volume Accurate ranking of treatment options Easy-to-use cosmic ray gun Portable nuclear warhead But the environment is… • VP maps onto CS • • No Value Proposition, no Customer Segment • Too many value propositions, not a Customer Segment VPs for each ‘customer’ in the ecosystem, to the extent possible 5
  • 6. How we will fit DX into the BMC CLINICAL TRIALS REGULATION IP REIMBURSEMENT 6
  • 7. Who is a Customer? • • • • Someone who has a NEED which can be satisfied by your VPs Someone who has a WANT which can be satisfied Someone who can be IDENTIFIED Someone who can be DIFFERENTIATED
  • 9. Customer Archetype: Joe “Dude” Marrama • Loves to ski, surf, rock climb • Salary ~100K/year • Looking for something to do when the surf’s blown out • Intimidated by cost and learning curve of kiting “Companies need to offer more entry level packages." Matt Sexton Founder Collegiate Kiteboarding Association
  • 10. Results: Our Customers • Professional Kite Surfers • Solely concerned with performance • Average Kite Surfer • Performance and cost sensitive • “One less thing to carry” effect • Prospective Kite Surfer • Cost sensitive • Learning barrier
  • 11. Meet Xing Xie International Graduate Student at Stanford • Engineering graduate student Xing Art – Receives financial package to cover tuition, fees, insurance and living expenses • Chinese 4-2-1 family – No siblings, spoiled by parents – High disposable income • 1st time to America – No credit score, SSN, or US address – Strong ties to his community in China • Academically responsible – Completes all homework on time • Financially responsible – Pays all bills on time and in full • Social network is similarly responsible
  • 12. Customer Segments? • • • • • • x Kids Boys Adults Kids under 10 with disposable income (and who are thirsty) Boys who like to watch machines working, like the juicer machine Dads and Moms who are walking past our stand in the afternoon Consider ‘Un-customer segments’ 12
  • 14. Definitions: Four Types of Markets Existing Market Resegmented Market New Market • Existing Market – Faster/Better = High end • Resegmented Market – Niche = marketing/branding driven – Cheaper = low end • New Market – Cheaper/good enough can create a new class of product/customer – Innovative/never existed before • Clone Market • Local adaptation Clone Market
  • 15. Because you are here..
  • 16. Because you are special… hypothesize now CLINICAL TRIALS IP REGULATION REIMBURSEMENT 16
  • 17. Know your regulator • Food and Drug Administration (FDA) – Center for Devices and Radiological Health • • • • • USDA European agencies (EMEA, national level) Japanese Ministry of Health and Welfare Chinese (SFDA) Health Canada
  • 18. Regulation • Invitro diagnostic products (IVD) are those reagents, instruments, and systems intended for use in diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. [21 CFR 809.3] • IVDs are medical devices as defined in section 210(h) of the Federal Food, Drug, and Cosmetic Act, and may also be biological products subject to section 351 of the Public Health Service Act. Like other medical devices, IVDs are subject to premarket and postmarket controls. IVDs are also subject to the Clinical Laboratory Improvement Amendments (CLIA '88) of 1988. • What isn’t an IVD? – – In vivo Treatments
  • 19. Regulatory classes for diagnostics • Class I (low to moderate risk): general controls • Class II (moderate to high risk): general controls and Special Controls (510(k)) aka PMN – – – – – • Performance standards Postmarket surveillance Patient registries Special labeling requirements Premarket data requirements Class III (high risk): general controls and Premarket Approval (PMA) – – Under federal law, class III devices are subject to approval of a Premarket Approval Application (PMA). Devices that are not within a type marketed before the date of the Medical Device Amendments of 1976 – referred to preamendments devices – are classified into class III automatically under federal law.. In addition, the FDA classifies into class III devices intended to be used in supporting or sustaining human life or preventing impairment of human health, or that may present a potential unreasonable risk of illness or injury for which general controls and special controls are insufficient to provide reasonable assurance of the safety and effectiveness of a device, or for which there is insufficient information to make such a determination. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm#class_1
  • 20. Believe it or not… Regulators are part of your customer set 1. Find out which regulator and sub-agency is likely to be yours 2. Find out the process for regulation and validation 3. Map them into your ecosystem
  • 21. Who pays for healthcare?
  • 22. What is Reimbursement? • Reimbursement for procedures and services performed by providers is made by commercial payers or federal intermediaries acting on behalf of a halfdozen programs. Reimbursement is based on claims and documentation filed by providers using medical diagnosis and procedure codes. • Commercial payers must use standards defined by the U.S. Department of Health and Human Services (HHS) but are largely regulated state-by-state. Save for specific national mandates such as reimbursement for childbirth, commercial payers determine their own rules of medical necessity or payment and reimbursement fee schedules. Federal intermediaries are regulated as contractors by the Centers for Medicare & Medicaid Services (CMS). • The Current Procedural Terminology (CPT) code set is a medical code set maintained by the American Medical Association. The CPT code set (copyright protected by the AMA) describes medical, surgical, and diagnostic services and is designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes
  • 23. Like it or not… Reimbursers and code allocators are part of your customer set 1. Find out which code groups you may fit into 2. Find out the value for them 3. Find out the process for assignment and approval 4. Map them into your ecosystem
  • 24. Next week • Standard slides as per the syllabus • Plus – Ecosystem overview – Regulation overview – Reimbursement overview

Editor's Notes

  1. Generally impacts some part of your business model diagram (usually NOT the product component)